O órgão odorífero abdominal do macho de Caligo arisbe Hbn. (Lepidoptera, Brassolidae)

1. O órgão odorífero do macho de Caligo arisbe é descrito morfológica e histològicamente. 2. O órgão consta de pares de placas glandulares de hipoderme com escamas odoríferas no quarto e quinto segmento do abdomen e de um aparelho auxiliar na asa posterior para a evaporação da secreção. 3. O aparelho auxiliar consta de 4 filas de cerdas e de uma área nua de evaporação com uma área em forma de anel com cerdas compridas. 4. Devido a falta de trabéculas as escamas odoríferas podem ser aumentadas em forma de vesícula. 5. O exame histológico demonstra nas células glandulares a presença de ergastoplasma e plastósomos grandes no pólo basal da célula. 6. A inserção é especialisada em alto grau. O pedúnculo da escama tem uma situação móvel o que facilita uma emissão da secreção em choque.

O órgão odorífero do macho de Mocis repanda Fabr., 1794 (Lepidoptera, Noctuidae, Sarrothripinae)

São descritos os órgãos odoríferos do macho de Mocis repanda. Foram encontrados: 1. Uma área com glândulas odoríferas na coxa anterior com um pincel-distribuidor no epímeron, fortemente modificado. o pincel abre-se automáticamente durante o movimento de deslocação da coxa para a frente. 2. Uma área de glândulas odoríferas nas arestas posteriores das tíbias e de todos os cinco artículos dos tarsos posteriores. O órgão inicialmente mencionado representa o tipo de um órgão complexo com o pincel-distribuidor inserindo-se fora da parea glandular. O outro, é um órgão simples, com escamas disseminadoras, que deixam evaporar a secreção das próprias células maternas. Por meio de observações com o microscópio eletrônico são descritas estruturas finas das escamas irradiadoras e distribuidoras formadas por micelas, até agora desconhecidas. As membranas das escamas disseminadoras, òticamente homogêneas, apresentam, ao microscópio eletrônico fios transversais, muito finos, com um diâmetro de apenas 0,057 micra. As estrias de ambas as fromas de escamas são compostas de finas escamas cobrindo-se uma ás outras, com a disposição de telhas. Elas são fixadas por trabéculas guardando uma distância uniforme entre si.

O órgão odorífero masculino de uma espécie do gênero Episimus (Lepidoptera, Olethreutidae)

Nesta comunicação descreve-se o aparelho odorífero masculino de uma espécie do grupo transferranus WLK., pergentcente ao gênero Episimus. Cosntra êle de um conjunto de células glandulares, localizadas na tégula, e de uma área glandular situada no interior de uma dobre na tégula, e de uma área glandular situada no interior de uma dobra membranosa, fortemente enrolada e disposta por baixo da articulação da asa posterior. As secreções dos dois tipos de células, que compõem as referidas formações, penetram num pincel de cerdas rígidas, através das quais se evaporam. A parte apical das referidas cerdas está, quando em repouso, escondida no interior da dobra do metatórax. Pelo fato de possuir duas funções bem marcadas, o dispositivo descrito foi chamado de "pincel irradiador-distribuidor". A ereção das cerdas é possibilitada pela membrana de inserção - bastante comprida - bem como por uma modificação de seu canal de inserção e pedúnculo. A energia necessária para o citado movimetno é fornecida pelo enchimento de dois grandes sacos traqueais do interior da tégula. Entre a tégula e a parede do tórax, encontra-se uma formação intercalada. Por contração muscular, a tégula sofre uma torsão no sentido lateral, de modo que o pincel, saindo do enrolamento indicado entra em contacto com o ar, permitindo a evaporação das secreções. Descreve-se, também, um "aparelho de fixação", formado por uma área provida de ganchos, situada no lado inferior da parte anal da asa anterior. Formação similar encontra-se no escuto do metatórax. Em posição de repouso, os ganchos das duas citadas áreas prendem-se entre si, mantendo fixa a posição das asas e proporcionando, assim, ao delicado aparelho odorífero, localizado por debaixo desta, uma proteção especial.

O órgão odorífero do macho de Athysania hesione Dry: (Lepidoptera, Noctuidae)

O órgão odorífero de Athysania hesione (e outras espécies próximas) está situado na face externa da segunda tíbia e compõe-se de uma região estreita tomada de células glandulares, situada no bordo posterior da tíbia cuja superfície externa forma um sulco longitudinal. Na parte proximal do núcleo insere-se um grande pincel distribuidor, cujas cerdas estão deitadas no sulco, onde entram em contato com as escamas odoríferas. Em virtude do enchimento de um saco traqueal, situado no interior da tíbia a pressão da hemolinfa aumenta, causando uma deformação da área de inserção do pincel que, por sua vez, sai do sulco, abrindo-se a fim de possibilitar a evaporação da secração. Depois da função, o pincel volta à posição de repouso graças à elasticidade da cutícula da área de inserção. O órgão é protegido por meio de séries de escamas protetoras de grandes superfícies. A célula glandular, excepcionalmente volumosa, localiza-se entre o sincício da hipoderme e a membrana basal (fig. 5). As células tricogêneas das cerdas do pincel distribuidor e das escamas protetoras possuíram, em épocas filogenéticas, função glandular; encontra-se, ainda hoje, no interior das primeiras, um aparelho excretor (fig. 9), sendo porém o seu núcleo e protoplasma completamente inativos, dando aos mesmo um aspecto de degenração.

Sôbre o órgão abdominal glandular de Arilus carinatus (Forster, 1771): (Heteroptera, Reduviidae)

Descreve-se um órgão glandular, encontrado na fêmea de Arilus carinatus, de um tipo ainda desocnhecido em insetos. Localiza-se, em forma de um saco membranoso, nos dois lados da linha ventral, entre os 8º e 9º segmentos abdominais. O órgão é expulso por um aumento da pressão interna da cavidade abdominal e volta ao estado de repouso, no interior do corpo, por meio de contração muscular. A vesícula retal volumosa forma, em direção distal, um amplo divertículo, do qual partem dois "tubos retais" que penetram nas vesículas membranosas, tendo na superfície destas uma abertura em forma de fenda. A hipoderme do divertículo, bem como a de uma região da vesícula retal e da parte basal dos tubos retais é glandular. A secreção possui um cheiro intenso e ardido que lembra o gás de acetileno. Trata-se, provàvelmente, de uma glândula repugnatória. Não se sabe nada sôbra a ocorrência do aparelho no macho e em outras espécies de Reduviídeos.

Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study

Introduction: We previously reported the results of a phase II study for patients with newly diagnosed primary CNS lymphoma (PCNSL) treated with autologous peripheral blood stem-cell transplantation (aPBSCT) and responseadapted whole brain radiotherapy (WBRT). The purpose of this report is to update the initial results and provide long-term data regarding overall survival, prognostic factors, and the risk of treatment-related neurotoxicity.Methods: A long-term follow-up was conducted on surviving primary central nervous system lymphoma patients having been treated according to the ,,OSHO-53 study", which was initiated by the Ostdeutsche Studiengruppe Hamatologie-Onkologie. Between August 1999 and October 2004 twentythree patients with an average age of 55 and median Karnofsky performance score of 70% were enrolled and received high-dose mthotrexate (HD-MTX) on days 1 and 10. In case of at least a partial remission (PR), high-dose busulfan/ thiotepa (HD-BuTT) followed by aPBSCT was performed. Patients without response to induction or without complete remission (CR) after HD-BuTT received WBRT. All patients (n=8), who are alive in 2011, were contacted and Mini Mental State examination (MMSE) and the EORTC QLQ-C30 were performed.Results: Eight patients are still alive with a median follow-up of 116,9 months (79 - 141, range). One of them suffered from a late relapse eight and a half years after initial diagnosis of PCNSL, another one suffers from a gall bladder carcinoma. Both patients are alive, the one with the relapse of PCNSL has finished rescue therapy and is further observed, the one with gall baldder carcinoma is still under therapy. MMSE and QlQ-C30 showed impressive results in the patients, who were not irradiated. Only one of the irradiated patients is still alive with a clear neurologic deficit but acceptable quality of life.Conclusions: Long-term follow-up of our patients, who were included in the OSHO-53 study show an overall survival of 30 percent. If WBRT can be avoided no long-term neurotoxicity has been observed and the patients benefit from excellent Quality of Life. Induction chemotherapy with two cycles of HD-MTX should be intensified to improve the unsatisfactory OAS of 30 percent.

The study of insect blood-feeding behaviour: 1. Feeding equipment, physical and endogenous factors, dose effect analysis, and diet destination

Experimental techniques that we have found useful during our studies of insect blood-feeding behaviour are reviewed. Some of the principal findings resulting from these techniques are discussed. Where directly applicable, the work of others is included, but no complete review of the subject has been attempted.

Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model.

INTRODUCTION: Solid tumors are known to have an abnormal vasculature that limits the distribution of chemotherapy. We have recently shown that tumor vessel modulation by low-dose photodynamic therapy (L-PDT) could improve the uptake of macromolecular chemotherapeutic agents such as liposomal doxorubicin (Liporubicin) administered subsequently. However, how this occurs is unknown. Convection, the main mechanism for drug transport between the intravascular and extravascular spaces, is mostly related to interstitial fluid pressure (IFP) and tumor blood flow (TBF). Here, we determined the changes of tumor and surrounding lung IFP and TBF before, during, and after vascular L-PDT. We also evaluated the effect of these changes on the distribution of Liporubicin administered intravenously (IV) in a lung sarcoma metastasis model. MATERIALS AND METHODS: A syngeneic methylcholanthrene-induced sarcoma cell line was implanted subpleurally in the lung of Fischer rats. Tumor/surrounding lung IFP and TBF changes induced by L-PDT were determined using the wick-in-needle technique and laser Doppler flowmetry, respectively. The spatial distribution of Liporubicin in tumor and lung tissues following IV drug administration was then assessed in L-PDT-pretreated animals and controls (no L-PDT) by epifluorescence microscopy. RESULTS: L-PDT significantly decreased tumor but not lung IFP compared to controls (no L-PDT) without affecting TBF. These conditions were associated with a significant improvement in Liporubicin distribution in tumor tissues compared to controls (P < .05). DISCUSSION: L-PDT specifically enhanced convection in blood vessels of tumor but not of normal lung tissue, which was associated with a significant improvement of Liporubicin distribution in tumors compared to controls.

A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.

BACKGROUND: EMD 521873 (Selectikine), an immunocytokine comprising a DNA-targeting antibody, aimed at tumour necrosis, fused with a genetically modified interleukin-2 (IL-2) moiety, was investigated in this first-in-human phase I study. METHODS: Patients had metastatic or locally advanced solid tumours failing previous standard therapy. Selectikine was administered as a 1-hour intravenous infusion on 3 consecutive days, every 3weeks. A subgroup of patients also received 300mg/m(2) cyclophosphamide on day 1 of each cycle. Escalating doses of Selectikine were investigated with the primary objective of determining the maximum tolerated dose (MTD). RESULTS: Thirty-nine patients were treated with Selectikine alone at dose levels from 0.075 to 0.9mg/kg, and nine were treated at doses of 0.45 and 0.6mg/kg in combination with cyclophosphamide. A dose-dependent linear increase of peak serum concentrations and area under curve was found. The dose-limiting toxicity was grade 3 skin rash at the 0.9mg/kg dose-level; the MTD was 0.6mg/kg. Rash and flu-like symptoms were the most frequent side-effects. No severe cardiovascular side-effects (hypotension or vascular leak) were observed. At all dose-levels, transient increases in total lymphocyte, eosinophil and monocyte counts were recorded. No objective tumour responses, but long periods of disease stabilisation were observed. Transient and non-neutralising Selectikine antibodies were detected in 69% of patients. CONCLUSIONS: The MTD of Selectikine with or without cyclophosphamide administered under this schedule was 0.6mg/kg. The recommended phase II dose was 0.45-0.6mg/kg. Selectikine had a favourable safety profile and induced biological effects typical for IL-2.

Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan.

The aim of the present study was to retrospectively estimate the absorbed dose to kidneys in 17 patients treated in clinical practice with 90Y-ibritumomab tiuxetan for non-Hodgkin's lymphoma, using appropriate dosimetric approaches available. METHODS: The single-view effective point source method, including background subtraction, is used for planar quantification of renal activity. Since the high uptake in the liver affects the activity estimate in the right kidney, the dose to the left kidney serves as a surrogate for the dose to both kidneys. Calculation of absorbed dose is based on the Medical Internal Radiation Dose methodology with adjustment for patient kidney mass. RESULTS: The median dose to kidneys, based on the left kidney only, is 2.1 mGy/MBq (range, 0.92-4.4), whereas a value of 2.5 mGy/MBq (range, 1.5-4.7) is obtained, considering the activity in both kidneys. CONCLUSIONS: Irrespective of the method, doses to kidneys obtained in the present study were about 10 times higher than the median dose of 0.22 mGy/MBq (range, 0.00-0.95) were originally reported from the study leading to Food and Drug Administration approval. Our results are in good agreement with kidney-dose estimates recently reported from high-dose myeloablative therapy with 90Y-ibritumomab tiuxetan.

A control flow prototype for a dose recommending device for chronic myeloid leukemia patients

In this paper we present a prototype of a control flow for an a posteriori drug dose adaptation for Chronic Myelogenous Leukemia (CML) patients. The control flow is modeled using Timed Automata extended with Tasks (TAT) model. The feedback loop of the control flow includes the decision-making process for drug dose adaptation. This is based on the outputs of the body response model represented by the Support Vector Machine (SVM) algorithm for drug concentration prediction. The decision is further checked for conformity with the dose level rules of a medical guideline. We also have developed an automatic code synthesizer for the icycom platform as an extension of the TIMES tool.

Successful treatment of trilateral retinoblastoma with conventional and high-dose chemotherapy plus radiotherapy: a case report.

Trilateral retinoblastoma (TRB) is a rare condition characterized by an intracranial neuroblastic tumor associated with bilateral or unilateral retinoblastoma (RB). The outcome is almost always fatal. An 18-month-old patient with familial bilateral RB was referred for a pineal lesion detected on a screening by magnetic resonance imaging. The child, considered inoperable by 2 different neurosurgical teams, was treated with conventional chemotherapy (methotrexate, vincristine, vepeside, cyclophosphamide, and carboplatin) plus tandem transplantation (vepeside/carboplatin and thiotepa/mephalan) followed by local radiotherapy. At 80 months from the diagnosis of TRB, the patient is alive and in complete remission, with no neuropsychologic consequences. An early and aggressive treatment may improve the prognosis of TRB.

Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.

This observational study analyzed imatinib pharmacokinetics and response in 2478 chronic myeloid leukemia (CML) patients. Data were obtained through centralized therapeutic drug monitoring (TDM) at median treatment duration of ≥2 years. First, individual initial trough concentrations under 400mg/day imatinib starting dose were estimated. Second, their correlation (C^min(400mg)) with reported treatment response was verified. Low imatinib levels were predicted in young male patients and those receiving P-gp/CYP3A4 inducers. These patients had also lower response rates (7% lower 18-months MMR in male, 17% lower 1-year CCyR in young patients, Kaplan-Meier estimates). Time-point independent multivariate regression confirmed a correlation of individual C^min(400mg) with response and adverse events. Possibly due to confounding factors (e.g. dose modifications, patient selection bias), the relationship seemed however flatter than previously reported from prospective controlled studies. Nonetheless, these observational results strongly suggest that a subgroup of patients could benefit from early dosage optimization assisted by TDM, because of lower imatinib concentrations and lower response rates.